Short Interest in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Expands By 26.1%
Short Interest in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Expands By 26.1%
Avalo Therapeutics, Inc. (NASDAQ:AVTX – Get Rating) was the recipient of a significant growth in short interest in the month of September. As of September 15th, there was short interest totalling 66,600 shares, a growth of 26.1% from the August 31st total of 52,800 shares. Currently, 0.8% of the company's shares are short sold. Based on an average daily trading volume, of 52,000 shares, the days-to-cover ratio is currently 1.3 days.
阿瓦洛治疗公司(纳斯达克代码：AVTX-GET评级)是9月份空头股数业务大幅增长的接受者。截至9月15日，空头股数共有66,600股，比8月31日的52,800股增长26.1%。目前，该公司0.8%的股票被卖空。以日均成交量52,000股计算，目前天数与回补比率为1.3天。
Avalo Therapeutics Stock Down 0.3 %
Avalo治疗公司股价下跌0.3%
Shares of Avalo Therapeutics stock opened at $3.32 on Friday. Avalo Therapeutics has a 1 year low of $2.42 and a 1 year high of $29.40. The business has a 50-day moving average of $4.36 and a two-hundred day moving average of $5.74. The company has a debt-to-equity ratio of 5.23, a quick ratio of 0.97 and a current ratio of 0.98.
周五，Avalo治疗公司的股票开盘报3.32美元。Avalo Treateutics的一年低点为2.42美元，一年高位为29.40美元。该业务的50日移动均线切入位在4.36美元，200日移动均线切入位在5.74美元。该公司的负债权益比率为5.23，速动比率为0.97，流动比率为0.98。
Avalo Therapeutics (NASDAQ:AVTX – Get Rating) last announced its quarterly earnings results on Thursday, August 4th. The company reported ($1.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.80) by $0.42. Avalo Therapeutics had a negative return on equity of 449.27% and a negative net margin of 1,896.95%. The company had revenue of $1.03 million during the quarter. Analysts anticipate that Avalo Therapeutics will post -2.79 EPS for the current year.
阿瓦洛治疗公司(纳斯达克代码：AVTX-GET评级)上一次公布季度收益是在8月4日星期四。该公司公布了本季度每股收益(EPS)(1.38美元)，比普遍预期的(1.80美元)高出0.42美元。阿瓦洛治疗公司的净资产回报率为负449.27%，净利润率为负1896.95%。该公司本季度营收为103万美元。分析师预计，阿瓦洛治疗公司本年度的每股收益将达到2.79美元。
Institutional Inflows and Outflows
机构资金流入和流出
Analyst Ratings Changes
分析师评级发生变化
Separately, Royal Bank of Canada cut their target price on Avalo Therapeutics from $24.00 to $21.00 in a research note on Monday, July 11th.
另外，加拿大皇家银行在7月11日星期一的一份研究报告中将阿瓦洛治疗公司的目标价从24美元下调至21美元。
Avalo Therapeutics Company Profile
Avalo治疗公司简介
(Get Rating)
(获取评级)
Avalo Therapeutics, Inc, a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome.
Avalo Treateutics，Inc.是一家临床阶段的精密药物公司，为免疫学、免疫肿瘤学和罕见遗传病方面未得到满足的临床需求的患者发现、开发和商业化靶向疗法。该公司开发了AVTX-002，这是一种完全人类抗光的单抗，正在进行第二阶段临床试验，用于治疗非嗜酸性哮喘以及炎症性肠道疾病，包括中到重度克罗恩病和溃疡性结肠炎；以及第三阶段临床试验，用于治疗新冠肺炎急性呼吸窘迫综合征。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on Avalo Therapeutics (AVTX)
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
- This Is A Memorable Time To Buy Into Micron Technology
- Let Paychex Stock Work Hard For You
- How Does Keurig Dr Pepper Compare To Larger Rivals Coke & Pepsi?
- 免费获取StockNews.com关于Avalo治疗公司(AVTX)的研究报告
- 电动汽车电池制造商Freyr将在全球大举扩张
- MarketBeat：回顾一周9/26-9/30
- 这是买入美光科技的难忘时刻
- 让Paychex股票为您努力工作
- Keurig Dr Pepper与规模更大的竞争对手可口可乐(Coke&Pepsi)相比如何？
Receive News & Ratings for Avalo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《阿瓦洛治疗日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Avalo治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。